GAS5 and breast cancer: The results obtained in the present study indicate that sorafenib mediated the up-regulation of GAS5 and the down-regulation of HOTTIP and HOXA-AS2 in most HCC, renal and breast cancer cells and probably their expression modulation may lead to a less aggressive cancer phenotype of the cells.